Veterinary Professionals Signal Strong Momentum for Regenerative Medicine
Nearly all veterinary professionals surveyed believe stem cell therapy is on track to become a standard treatment option within the next decade.
Gallant, in collaboration with the American Animal Hospital Association (AAHA), has released findings from a national survey exploring how veterinary professionals view regenerative medicine and the evolving role of stem cell therapy in clinical practice. The survey gathered insights from 1,095 U.S. small animal veterinary professionals and offers a snapshot of where the profession stands as regenerative therapies move closer to mainstream adoption.
Current Care: Effective, but Often Symptom-Focused
Across practice types, respondents expressed a clear and consistent theme: today’s standard treatments for inflammatory diseases often manage clinical signs but do not address the underlying disease process.
According to the survey:
This perspective reflects what many veterinary teams experience daily. Chronic conditions such as osteoarthritis, immune-mediated diseases, and oral inflammatory disorders remain challenging to manage long term. While existing therapies play an essential role in care, there is interest in approaches that may influence disease biology more directly.
A Profession Preparing for What’s Next
The survey results also signal strong forward-looking momentum.
These findings suggest that the veterinary community is not only aware of regenerative medicine – but actively preparing for its integration into everyday practice. Convenience, regulatory oversight, and clear clinical protocols matter. So does education. The profession is signaling readiness, along with a desire for credible training, peer-reviewed data and practical implementation support.
Building a New Category Responsibly
As regenerative medicine advances toward broader regulatory approval and clinical adoption, responsible leadership is essential.
“Clinicians want more tools to help pets living with inflammatory diseases,” said Dr. Linda Black, CEO of Gallant. “They are looking to expand the spectrum of care with options that may address disease at a deeper level.”
Gallant is focused on advancing FDA-regulated, off-the-shelf allogeneic stem cell therapies designed for use in everyday veterinary practice. Alongside product development, Gallant offers RACE-approved continuing education through GallantU, providing live and on-demand courses covering stem cell biology, clinical application, immunomodulatory mechanisms, and emerging evidence across indications.
As interest accelerates, education, clarity, and real-world implementation support will shape how regenerative medicine integrates into the standard of care.
The survey findings reinforce a clear message: veterinary professionals recognize the limitations of symptom-only management and are open to disease-modifying innovation when it is grounded in science, supported by evidence and practical to deliver.
Gallant remains committed to building this new category with rigor, transparency and partnership at the center.
Download the Gallant + AAHA Regenerative Medicine Survey one-pager
